A surreal digital illustration symbolizing kidney protection during immunotherapy.

Kidney Alert: How Common Medications Can Turn Toxic During Immunotherapy

Reese Marlowe monogram
Reese Marlowe in Health & Wellness October 2026 • 4 min read.

"Uncover the hidden risks of combining immunotherapy with everyday drugs and learn how to protect your kidney health."


Immunotherapy, a revolutionary approach in cancer treatment, harnesses the power of the body's immune system to fight cancer cells. While these treatments, particularly immune checkpoint inhibitors (ICPIs) like anti-PD-1 and anti-CTLA-4 antibodies, have shown remarkable success, they also come with a unique set of challenges. One increasingly recognized complication is acute tubulointerstitial nephritis (ATIN), a type of kidney injury.

ATIN occurs when the spaces between the kidney tubules become inflamed, disrupting normal kidney function. ICPIs can sometimes trigger this inflammation, leading to kidney damage. What makes this situation particularly complex is that the interaction between immunotherapy and other medications a patient is taking can significantly increase the risk of ATIN. This means drugs that have been safely used for years can suddenly become problematic when combined with these cancer treatments.

This article explores the intricate link between ICPIs, seemingly harmless medications, and kidney health, emphasizing the critical need for awareness and careful management of drug combinations during immunotherapy. We will delve into a compelling case study that highlights this risk, offering valuable insights for patients and healthcare professionals alike.

AI Search Multiple angles on this topic

Immunotherapy’s Role and Challenges

The National Cancer Institute describes immunotherapy as a cancer treatment that helps the immune system fight cancer. The American Cancer Society likewise defines it as treatment using the body's own immune system to help fight cancer and notes that immunotherapies can have side effects. Cancer immunotherapy also faces the clinical challenge of treatment resistance, which can reduce its efficacy.

Benefits and Risks

Immunotherapy works with the immune system as a treatment approach for cancer. WebMD presents immunotherapy in terms of both potential benefits and risks, including possible side effects. This balance means that treatment decisions require attention not only to how immunotherapy treats cancer but also to its potential harms.

An Evolving Treatment Field

Immunotherapy is best understood as an evolving field built around using or modifying the immune system to address disease. Its development has produced multiple therapeutic strategies rather than one uniform treatment. A detailed historical timeline cannot be established from the available source material.

The Silent Threat: When Safe Medications Become Dangerous

A surreal digital illustration symbolizing kidney protection during immunotherapy.

One of the major concerns with ICPIs is their potential to disrupt the body's established immune tolerance to various substances, including medications. Immune tolerance is the process by which the immune system learns to recognize and ignore certain substances, preventing it from launching an attack against them. ICPIs can interfere with this process, causing the immune system to react to drugs that were previously well-tolerated.

Consider the following case: A 67-year-old man undergoing treatment for stage IV non-small-cell lung cancer developed kidney injury during nivolumab therapy, an anti-PD-1 antibody. A kidney biopsy confirmed ATIN. What was particularly striking was that for over four years before starting nivolumab, the patient had been taking lansoprazole, a proton pump inhibitor (PPI), to manage acid reflux. Lansoprazole is a known cause of drug-induced ATIN, but the patient had experienced no kidney problems during those four years.

  • The Culprit: Lansoprazole, a common PPI, which had been safely used for years.
  • The Trigger: Nivolumab, an anti-PD-1 antibody, disrupting immune tolerance.
  • The Result: Acute tubulointerstitial nephritis (ATIN), leading to kidney injury.
AI Search Multiple angles on this topic

Current Evidence

The available material describes immunotherapy broadly as a group of strategies that harness or modify the immune system. It does not provide a specific new study, review, dataset, or recent research finding about kidney toxicity during immunotherapy. Any detailed claim about the latest evidence would therefore require additional sources.

Treatment Resistance

A central limitation of cancer immunotherapy is that cancer cells can develop resistance to treatment. This resistance decreases the efficacy of immunotherapy and represents a significant clinical challenge. The available material does not establish how often resistance occurs or identify a particular failed treatment.

Different Immunotherapy Strategies

Immunotherapy encompasses a diverse set of therapeutic strategies that harness or modify the immune system. Because the available material does not compare named therapies, outcomes, or toxicity rates, it cannot support a direct ranking of approaches. Comparisons would require evidence specific to the treatments being evaluated.

After nivolumab treatment began, the patient's immune system appeared to lose its tolerance to lansoprazole, triggering an inflammatory response in the kidneys. The situation improved rapidly once lansoprazole was stopped, highlighting the importance of recognizing and discontinuing potentially harmful medications during immunotherapy. A drug-induced lymphocyte stimulation test (DLST) confirmed that lansoprazole was the culprit.

Protecting Your Kidneys: A Call to Vigilance

This case underscores the importance of vigilance and careful drug management during immunotherapy. While corticosteroids are often recommended to manage ICPI-associated kidney injury, recognizing and discontinuing concomitant drugs, especially those known to cause ATIN, is essential. Patients and healthcare providers must work together to ensure all medications are carefully reviewed and monitored throughout the treatment process.

AI Search Multiple angles on this topic

Balancing Immune Activity and Risk

Taken together, the available sources portray immunotherapy as a treatment that recruits or modifies the body's immune response against cancer. They also indicate that side effects and treatment resistance are important limitations. The material supports a careful risk-benefit discussion but does not provide expert commentary specifically on medication-related kidney toxicity.

An Expanding Therapeutic Landscape

The diversity of immunotherapy strategies suggests that the field may continue to develop in multiple directions. However, the available material does not identify specific future therapies, research targets, or projections. Claims about next frontiers should therefore remain tentative without additional evidence.

Complexity in Cancer Care

Immunotherapy is a broad category of biological treatment rather than a single standardized intervention. Its wider challenges include possible side effects and the ability of cancer cells to develop treatment resistance. The available sources do not describe healthcare-system factors, access barriers, or broader population effects.

Patient-Centered Tradeoffs

For patients, immunotherapy offers an approach that uses the body's own immune system to help fight cancer. At the same time, possible side effects and reduced efficacy from treatment resistance can complicate the treatment experience. The available material does not provide patient stories, quality-of-life data, or specific real-world outcomes.

What keeps this case from settling causation

  • The test’s accuracy for PPI-related ATIN has not been established; a positive result alone cannot prove the cause.[1]
  • The authors note that additional case reports with drug-test results are needed to clarify the process and practical management.[2]

The case report at a glance

PopulationA 67-year-old Japanese man with stage IV non-small-cell lung cancer[2]
DurationMore than 4 years of lansoprazole use before nivolumab initiation[2]
ComparisonBaseline kidney function before nivolumab therapy[2]
Effect sizeCreatinine decreased from 2.74 to 1.82 mg/dl in 3 days after lansoprazole discontinuation[2]
Conflicts of interestNo competing interests declared[2]
Times cited77[2]

How this case fits with other kidney-injury reports

A six-case report series described biopsy-confirmed ATIN during nivolumab or pembrolizumab treatment in lung cancer, placing this report alongside other checkpoint-inhibitor cases rather than establishing a general rate.[1]

In a biopsy-based single-center series, PPIs accounted for 13 of 95 drug-induced ATIN cases; that finding gives context for lansoprazole as a possible contributor, not a risk estimate for patients receiving immunotherapy.[1]

What a follow-up would need to show

  • Would testing before and after checkpoint-inhibitor treatment show whether immune responsiveness to a previously tolerated medication changed?[1]
  • How reliably does the lymphocyte stimulation test identify a culprit drug in PPI-associated ATIN?[1]
  • Across additional cases, how often does kidney function improve after withdrawal of a suspected concomitant drug, and how often does injury recur with renewed exposure?[1] [2]

Questions about the case

Did the patient’s kidney function return to its earlier level?

No. The paper says it did not return to the baseline after steroid therapy and suggests tissue fibrosis and tubular atrophy may explain why.[1]

Sources

  1. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report (Europe PMC, 2018)
  2. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report (Springer Science and Business Media LLC, 2018)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1186/s12882-018-0848-y, Alternate LINK

Title: Immune Checkpoint Inhibitor (Nivolumab)-Associated Kidney Injury And The Importance Of Recognizing Concomitant Medications Known To Cause Acute Tubulointerstitial Nephritis: A Case Report

Subject: Nephrology

Journal: BMC Nephrology

Publisher: Springer Science and Business Media LLC

Authors: Ryo Koda, Hirofumi Watanabe, Masafumi Tsuchida, Noriaki Iino, Kazuo Suzuki, Go Hasegawa, Naofumi Imai, Ichiei Narita

Published: 2018-02-27

Everything You Need To Know

1

What is immunotherapy and how does it relate to kidney health?

Immunotherapy is a cancer treatment approach that leverages the body's immune system to fight cancer cells. Specifically, immune checkpoint inhibitors (ICPIs), like anti-PD-1 and anti-CTLA-4 antibodies, are a type of immunotherapy. While effective, ICPIs can sometimes lead to acute tubulointerstitial nephritis (ATIN), a kidney injury. This is because ICPIs can disrupt the body's immune tolerance, causing it to react to medications that were previously harmless, which in turn can trigger inflammation in the kidneys and lead to kidney damage.

2

How can seemingly safe medications become dangerous when combined with immunotherapy?

The danger arises because ICPIs, such as anti-PD-1 antibodies, can disrupt the body's immune tolerance. Immune tolerance is the process where the immune system recognizes and ignores certain substances, including medications. When ICPIs interfere with this, the immune system may start attacking drugs that were previously well-tolerated. A specific case involves lansoprazole, a proton pump inhibitor (PPI), which, when combined with the anti-PD-1 antibody nivolumab, caused ATIN in a patient who had safely used lansoprazole for years.

3

What is Acute Tubulointerstitial Nephritis (ATIN), and why is it relevant in the context of immunotherapy?

ATIN is a type of kidney injury where the spaces between the kidney tubules become inflamed, disrupting normal kidney function. In the context of immunotherapy, specifically with ICPIs, ATIN is a concerning complication. ICPIs can trigger this inflammation, potentially leading to kidney damage. The risk is increased when ICPIs interact with other medications, which can result in the development of ATIN even with drugs that have been safely used for a long time.

4

Can you explain the specific case involving lansoprazole and nivolumab and the implications?

In the case study, a 67-year-old man with stage IV non-small-cell lung cancer developed kidney injury while undergoing nivolumab (an anti-PD-1 antibody) therapy. The patient was also taking lansoprazole, a PPI, for acid reflux. The kidney injury was diagnosed as ATIN. The key point is that the patient had been safely taking lansoprazole for four years before nivolumab treatment. After starting nivolumab, his immune system seemingly lost its tolerance to lansoprazole, leading to an inflammatory response in the kidneys. This highlights that ICPIs like nivolumab can make safe drugs, like lansoprazole, dangerous, emphasizing the need to carefully review and monitor medications during immunotherapy.

5

What steps can be taken to protect kidney health during immunotherapy?

Protecting kidney health during immunotherapy requires vigilance and careful drug management. Healthcare providers and patients need to work together to ensure all medications are thoroughly reviewed and monitored throughout the treatment process. If kidney injury arises, recognizing and discontinuing concomitant drugs, especially those known to cause ATIN, is essential. While corticosteroids are often used to manage ICPI-associated kidney injury, identifying and addressing the offending medications, such as lansoprazole in the case study, is crucial for a positive outcome. The key is proactive monitoring and awareness of potential drug interactions.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.